The Centers for Medicare & Medicaid Services (CMS) proposed removing the coverage with evidence development (CED) requirement for Transcatheter Aortic Valve Replacement (TAVR) in patients with symptomatic severe aortic stenosis. This move aims to broaden access to the heart valve device, a significant development for Edwards Lifesciences Corp. The proposal also includes expanding TAVR coverage to asymptomatic severe aortic stenosis patients under CED and updating coverage criteria for pre-procedure evaluations, intraoperative standards, and operator and hospital volume requirements.

William Blair analyst Brandon Vazquez described the update as a win for Edwards Lifesciences, noting it validates the thesis following the National Coverage Determination (NCD) opening in December. The proposal aligns with the EARLY TAVR data and the FDA's April 2025 expansion of the SAPIEN 3 label. Edwards currently holds the only FDA-approved TAVR device indicated for asymptomatic severe aortic stenosis patients, positioning the company for a competitive advantage if the coverage is finalized.

CMS Proposes Changes To TAVR Coverage Requirements

Aortic stenosis involves the narrowing or stiffening of the heart's aortic valve, restricting blood flow from the heart to the body. The CMS proposal seeks to simplify the treatment pathway and enable patients to access therapy sooner. The continued data collection under CED for asymptomatic patients is expected to benefit stakeholders across the healthcare system.

Analyst Views CMS Proposal As Positive For Edwards Lifesciences

William Blair maintains an Outperform rating for Edwards Lifesciences. The implementation of the NCD could catalyze TAVR adoption by streamlining the treatment process. Edwards Lifesciences shares were up 3.74% at $88.65 at the time of publication on Tuesday, reflecting market optimism about the proposed changes.

RBC Capital analyst Shagun Singh has reiterated an Outperform rating for Edwards Lifesciences, maintaining a price target of $100. The rating affirmation underscores confidence in the company's market position.

Analyst Rating and Price Target

The research note highlights the firm's continued positive outlook on Edwards Lifesciences. The $100 price target remains unchanged, suggesting potential upside from current levels.